Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03510897




Registration number
NCT03510897
Ethics application status
Date submitted
18/04/2018
Date registered
27/04/2018
Date last updated
16/07/2021

Titles & IDs
Public title
QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
Scientific title
A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for Acute Kidney Injury (AKI) Following Cardiac Surgery
Secondary ID [1] 0 0
QRK309
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cardiac Surgery 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - teprasiran
Treatment: Drugs - Placebo

Active comparator: QPI-1002 - QPI-1002 Injection, Single dose

Placebo comparator: Placebo - isotonic saline


Treatment: Drugs: teprasiran
IV injection

Treatment: Drugs: Placebo
isotonic saline
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of subjects through day 90 who develop major adverse kidney events
Timepoint [1] 0 0
Baseline through day 90
Secondary outcome [1] 0 0
Proportion of subjects developing AKI overall by modified AKIN criteria within 5 days post-surgery
Timepoint [1] 0 0
Baseline through day 5
Secondary outcome [2] 0 0
Renal function as estimated by glomerular filtration rate
Timepoint [2] 0 0
Baseline through Day 90
Secondary outcome [3] 0 0
Proportion of subjects who die or initiate dialysis through day 90
Timepoint [3] 0 0
Baseline through day 90

Eligibility
Key inclusion criteria
Key

* Male or female, age = 18 years old
* At risk for AKI following cardiac surgery on the basis of at least one of the following pre-operatively assessed risk factors:

* Reduced renal function
* Diabetes with ongoing insulin treatment
* Albuminuria
* Undergoes non-emergent open chest cavity cardiovascular surgeries, with use of cardiopulmonary bypass (CPB), with or without hypothermic circulatory arrest

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Emergent surgeries, including aortic dissection, and major congenital heart defects
* Undergoes cardiac surgery off CPB for subjects =45 years old. (Cardiac surgery off CPB for subjects <45 years old is allowed.)
* Perioperative or post cardiac surgery, an left ventricular assist device (LVAD) is inserted or anticipated

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/06/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
12/04/2021
Sample size
Target
Accrual to date
Final
1043
Recruitment in Australia
Recruitment state(s)
NSW,QeenslandQLD,SA,VIC
Recruitment hospital [1] 0 0
Westmead Hospital - Westmead
Recruitment hospital [2] 0 0
The Prince Charles Hospital - Chermside
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 0 0
The Townsville Hospital - Douglas
Recruitment hospital [5] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [6] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [7] 0 0
St. Vincent's Hospital Melbourne - Fitzroy
Recruitment hospital [8] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [9] 0 0
The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
4032 - Chermside
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
4814 - Douglas
Recruitment postcode(s) [5] 0 0
5042 - Bedford Park
Recruitment postcode(s) [6] 0 0
3168 - Clayton
Recruitment postcode(s) [7] 0 0
3065 - Fitzroy
Recruitment postcode(s) [8] 0 0
3084 - Heidelberg
Recruitment postcode(s) [9] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nebraska
Country [13] 0 0
United States of America
State/province [13] 0 0
New Hampshire
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Austria
State/province [24] 0 0
Tyrol
Country [25] 0 0
Austria
State/province [25] 0 0
Upper Austria
Country [26] 0 0
Austria
State/province [26] 0 0
Wien
Country [27] 0 0
Belgium
State/province [27] 0 0
Leuven
Country [28] 0 0
Canada
State/province [28] 0 0
Alberta
Country [29] 0 0
Canada
State/province [29] 0 0
British Columbia
Country [30] 0 0
Canada
State/province [30] 0 0
Manitoba
Country [31] 0 0
Canada
State/province [31] 0 0
New Brunswick
Country [32] 0 0
Canada
State/province [32] 0 0
Ontario
Country [33] 0 0
Canada
State/province [33] 0 0
Quebec
Country [34] 0 0
Czechia
State/province [34] 0 0
Hradec Králové
Country [35] 0 0
Czechia
State/province [35] 0 0
Praha 4
Country [36] 0 0
Czechia
State/province [36] 0 0
Praha 5
Country [37] 0 0
France
State/province [37] 0 0
Besançon
Country [38] 0 0
France
State/province [38] 0 0
Grenoble Cedex 9
Country [39] 0 0
France
State/province [39] 0 0
Pessac Cedex
Country [40] 0 0
France
State/province [40] 0 0
Reims
Country [41] 0 0
France
State/province [41] 0 0
Rennes
Country [42] 0 0
France
State/province [42] 0 0
Strasbourg Cedex
Country [43] 0 0
France
State/province [43] 0 0
Toulouse
Country [44] 0 0
Germany
State/province [44] 0 0
Bavaria
Country [45] 0 0
Germany
State/province [45] 0 0
Brandenburg
Country [46] 0 0
Germany
State/province [46] 0 0
Deutschland
Country [47] 0 0
Germany
State/province [47] 0 0
Hesse
Country [48] 0 0
Germany
State/province [48] 0 0
Lower Saxony
Country [49] 0 0
Germany
State/province [49] 0 0
Rhineland-Palatinate
Country [50] 0 0
Germany
State/province [50] 0 0
Saxony
Country [51] 0 0
Germany
State/province [51] 0 0
Bad Krozingen
Country [52] 0 0
Germany
State/province [52] 0 0
Bad Neustadt An Der Saale
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Germany
State/province [54] 0 0
Bonn
Country [55] 0 0
Germany
State/province [55] 0 0
Dresden
Country [56] 0 0
Germany
State/province [56] 0 0
Essen
Country [57] 0 0
Germany
State/province [57] 0 0
Heidelberg
Country [58] 0 0
Germany
State/province [58] 0 0
Lubeck
Country [59] 0 0
Germany
State/province [59] 0 0
Mainz
Country [60] 0 0
Germany
State/province [60] 0 0
München
Country [61] 0 0
New Zealand
State/province [61] 0 0
Auckland
Country [62] 0 0
New Zealand
State/province [62] 0 0
Hamilton
Country [63] 0 0
New Zealand
State/province [63] 0 0
Wellington
Country [64] 0 0
Spain
State/province [64] 0 0
A Coruña
Country [65] 0 0
Spain
State/province [65] 0 0
Barcelona
Country [66] 0 0
Spain
State/province [66] 0 0
Cordoba
Country [67] 0 0
Spain
State/province [67] 0 0
Navarra
Country [68] 0 0
Spain
State/province [68] 0 0
Barakaldo
Country [69] 0 0
Spain
State/province [69] 0 0
Madrid
Country [70] 0 0
Spain
State/province [70] 0 0
Oviedo
Country [71] 0 0
Spain
State/province [71] 0 0
Valencia
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Cambridgeshire
Country [73] 0 0
United Kingdom
State/province [73] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Quark Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
Trial website
https://clinicaltrials.gov/study/NCT03510897
Trial related presentations / publications
Thielmann M, Corteville D, Szabo G, Swaminathan M, Lamy A, Lehner LJ, Brown CD, Noiseux N, Atta MG, Squiers EC, Erlich S, Rothenstein D, Molitoris B, Mazer CD. Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study. Circulation. 2021 Oct 5;144(14):1133-1144. doi: 10.1161/CIRCULATIONAHA.120.053029. Epub 2021 Sep 3.
Hinze C, Karaiskos N, Boltengagen A, Walentin K, Redo K, Himmerkus N, Bleich M, Potter SS, Potter AS, Eckardt KU, Kocks C, Rajewsky N, Schmidt-Ott KM. Kidney Single-cell Transcriptomes Predict Spatial Corticomedullary Gene Expression and Tissue Osmolality Gradients. J Am Soc Nephrol. 2021 Feb;32(2):291-306. doi: 10.1681/ASN.2020070930. Epub 2020 Nov 25.
Public notes

Contacts
Principal investigator
Name 0 0
Nitsan Halevy, MD
Address 0 0
Quark Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03510897